Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers
- PMID: 33674744
- PMCID: PMC8032555
- DOI: 10.1038/s41388-021-01710-y
Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers
Abstract
Targeting PARP1 [Poly(ADP-Ribose) Polymerase 1] for synthetic lethality is a new strategy for BRCA germ-line mutated or platinum sensitive ovarian cancers. However, not all patients respond due to intrinsic or acquired resistance to PARP1 inhibitor. Development of alternative synthetic lethality approaches is a high priority. DNA polymerase β (Polβ), a critical player in base excision repair (BER), interacts with PARP1 during DNA repair. Here we show that polβ deficiency is a predictor of platinum sensitivity in human ovarian tumours. Polβ depletion not only increased platinum sensitivity but also reduced invasion, migration and impaired EMT (epithelial to mesenchymal transition) of ovarian cancer cells. Polβ small molecular inhibitors (Pamoic acid and NSC666719) were selectively toxic to BRCA2 deficient cells and associated with double-strand breaks (DSB) accumulation, cell cycle arrest and increased apoptosis. Interestingly, PARG [Poly(ADP-Ribose) Glycohydrolase] inhibitor (PDD00017273) [but not PARP1 inhibitor (Olaparib)] was synthetically lethal in polβ deficient cells. Selective toxicity to PDD00017273 was associated with poly (ADP-ribose) accumulation, reduced nicotinamide adenine dinucleotide (NAD+) level, DSB accumulation, cell cycle arrest and increased apoptosis. In human tumours, polβ-PARG co-expression adversely impacted survival in patients. Our data provide evidence that polβ targeting is a novel strategy and warrants further pharmaceutical development in epithelial ovarian cancers.
Conflict of interest statement
The authors declare no competing interests.
Figures






Similar articles
-
ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.Gynecol Oncol. 2019 May;153(2):416-424. doi: 10.1016/j.ygyno.2019.02.014. Epub 2019 Feb 21. Gynecol Oncol. 2019. PMID: 30797591
-
PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.Cancer Lett. 2020 Jan 28;469:124-133. doi: 10.1016/j.canlet.2019.10.035. Epub 2019 Oct 24. Cancer Lett. 2020. PMID: 31669203
-
Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers.Theranostics. 2021 Jul 25;11(17):8350-8361. doi: 10.7150/thno.51456. eCollection 2021. Theranostics. 2021. PMID: 34373746 Free PMC article.
-
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6. J Ovarian Res. 2019. PMID: 30691488 Free PMC article. Review.
-
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.J Oncol Pharm Pract. 2017 Sep;23(6):454-469. doi: 10.1177/1078155216657165. Epub 2016 Jun 29. J Oncol Pharm Pract. 2017. PMID: 27357817 Review.
Cited by
-
DePARylation is critical for S phase progression and cell survival.Elife. 2024 Apr 5;12:RP89303. doi: 10.7554/eLife.89303. Elife. 2024. PMID: 38578205 Free PMC article.
-
Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers.Sci Adv. 2023 Nov 3;9(44):eadh4379. doi: 10.1126/sciadv.adh4379. Epub 2023 Nov 1. Sci Adv. 2023. PMID: 37910620 Free PMC article.
-
Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.DNA Repair (Amst). 2024 Aug;140:103700. doi: 10.1016/j.dnarep.2024.103700. Epub 2024 Jun 4. DNA Repair (Amst). 2024. PMID: 38897003 Free PMC article.
-
Evolving DNA repair synthetic lethality targets in cancer.Biosci Rep. 2022 Dec 22;42(12):BSR20221713. doi: 10.1042/BSR20221713. Biosci Rep. 2022. PMID: 36420962 Free PMC article.
-
Suppression of DNA Polymerase β Activity Is Synthetically Lethal in BRCA1-Deficient Cells.ACS Chem Biol. 2021 Aug 20;16(8):1339-1343. doi: 10.1021/acschembio.1c00385. Epub 2021 Jul 9. ACS Chem Biol. 2021. PMID: 34240844 Free PMC article.
References
-
- Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–505. - PubMed
-
- Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl J Med. 2016;375:2154–64. - PubMed
-
- Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75–87. - PubMed
-
- D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair. 2018;7:172–6. - PubMed
-
- Lindahl T. Repair of intrinsic DNA lesions. Mutat Res. 1990;238:305–11. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous